Evidence map›Paper›PMID 29018828›Full record

ArticleJournal of diabetes research2017

Repurposing Lesogaberan to Promote Human Islet Cell Survival and

Jide Tian, Hoa Dang, Angela Hu, Willem Xu, Daniel L Kaufman

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Gamma-aminobutyric acid for delaying type 1 diabetes mellitus: an update.Annals of pediatric endocrinology & metabolism · 2024
    Article
  2. The role of GABA in type 1 diabetes.Frontiers in endocrinology · 2024
    Review
  3. GABACurrent topics in behavioral neurosciences · 2022
    Review
  4. GABABiomedicines · 2021
    Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jide TianDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Hoa DangDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Angela HuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Willem XuDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Daniel L KaufmanDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.ORCID 0000-0002-9844-5918
University of California, Los Angeles · US

Funding

Reversal of T1D in NOD mice using a safe combination therapyR01DK092480 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAUFMAN, DANIEL · 2012 to 2015
$1.3M
Repurposing lesogaberan for the treatment of type 1 diabetesR21TR001742 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAUFMAN, DANIEL · 2016 to 2017
$616k
NCATS NIH HHS R21 TR001742NIDDK NIH HHS R01 DK092480
6 · The paper itself

Abstract

The activation of

Indexed as

Drug RepositioningAnimalsApoptosisCell ProliferationCell SurvivalDiabetes Mellitus, ExperimentalGABA-B Receptor AgonistsGABA-B Receptor AntagonistsHumansHypoglycemic AgentsImmunohistochemistryInsulin-Secreting CellsIslets of LangerhansIslets of Langerhans TransplantationMice, SCIDPhosphinic AcidsGABA-B Receptor AgonistsGABA-B Receptor AntagonistsHypoglycemic AgentslesogaberanPhosphinic AcidsPropylamines

Identifiers

PMID29018828
PMCPMC5605788
OpenAlexW2750673972

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.